LDX-01 plus TAU
Phase 2Small molecule
LDX-01 plus TAU is one of 2 small molecule programs targeting Methamphetamine Use Disorder. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Methamphetamine Use Disorder
#DrugCompanyPhaseTrials
1Psilocybin
COMPASS PathwaysPhase 2
LDX-01 plus TAU
CCentre hospitalier de l'Université de Montréal (CHUM)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Methamphetamine Use Disorder1 trial
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
Recruiting·—·Phase 2·NCT06788587·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LDX-01 plus TAU. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details